INLYTA is a prescription medicine used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC) when one prior drug treatment for this disease has not worked or has stopped working. This is often referred to as second-line treatment.)
In a trial, INLYTA extended median progression-free survival (PFS) for some advanced RCC patients compared with others taking Nexavar® (sorafenib).
- Extended median (PFS) by 2 months compared to Nexavar In this study, those who were treated with INLYTA experienced a median PFS of 6.7 months compared with 4.7 months among patients who were taking Nexavar. That’s a 43% increase in median PFS.
- One-third less risk of progression In this study, the overall risk of disease progression, such as tumor growth or spread, or death, was decreased by about one-third with INLYTA compared to Nexavar.
- Neither medicine showed an advantage in overall survival This study also measured the total time patients on each medicine remained alive after starting treatment. There was no significant difference in overall survival between the patients taking INLYTA and the patients taking Nexavar.
- More than twice as many INLYTA patients saw their tumors shrink (overall response rate) Twice as many patients on INLYTA saw their tumors shrink (70 of 361 patients taking INLYTA compared with 34 of 362 patients taking Nexavar).
INLYTA is not a cure. The data represent an average and not all patients may experience the same results.